News|Articles|November 20, 2026

Testosterone Therapy Shows No Added Progression Risk in Active Surveillance PCa

Fact checked by: Roman Fabbricatore

Testosterone therapy was not associated with disease progression in a retrospective 3324-patient active surveillance prostate cancer cohort.

Testosterone therapy (TTh) for testosterone deficiency (TD) did not significantly affect the risk of disease progression in men with prostate cancer (PCa) on active surveillance (AS), according to results from a retrospective cohort study published in The Journal of Urology.1

Among the 3324-patient cohort enrolled at a single academic center, 1256 (38%) experienced biopsy-confirmed disease progression during follow-up. Progression-free probabilities for the entire cohort were 88% (95% CI, 87%-89%) at 2.5 years, 70% (95% CI, 68%-72%) at 5 years, 60% (95% CI, 58%-62%) at 7.5 years, and 53% (95% CI, 51%-55%) at 10 years. On multivariable analysis, in which TTh was modeled as a time-dependent covariate to account for the variable timing of TTh initiation after AS enrollment, TTh was not significantly associated with the risk of histologic disease progression (HR, 0.99; 95% CI, 0.67-1.48; P >.9). Adjusted survival curves showed no clinically meaningful difference in event rates between patients receiving concurrent TTh and those who were not.

TTh similarly did not affect the secondary outcome of progression to definitive treatment (HR, 0.94; 95% CI, 0.64-1.38; P = 0.8). Among the 2068 patients who did not experience biopsy-based progression, 163 proceeded to definitive therapy, including radical prostatectomy, radiation therapy (RT), or focal therapy, and 1905 remained on AS as of their last known follow-up. The median follow-up from PCa diagnosis for patients who neither progressed nor proceeded to treatment was 7 years (IQR, 4.6-10.3).

"We found no evidence that TTh increased the risk of disease progression or crossover to definitive treatment in men with testosterone deficiency enrolled in a PCa AS program. The results suggest that TTh may be appropriate for PCa patients undergoing a closely monitored AS program, and further research is necessary to confirm oncologic safety with larger and more mature cohorts," Jose M. Flores, MD, MHA, assistant attending surgeon in the Sexual & Reproductive Medicine Program at Memorial Sloan Kettering Cancer Center (MSKCC) and lead author, wrote in the publication with study coinvestigators.1

This retrospective cohort study used prospectively collected data from men enrolled in the AS program at MSKCC between January 2007 and July 2023. Patients with International Society of Urological Pathology (ISUP) grade group (GG) 1 or select favorable GG2 PCa were eligible for AS. Among the 3324 patients, 79 received concurrent TTh. Eligibility for TTh required a total serum testosterone below 300 ng/dL on 2 occasions (measured by liquid chromatography–mass spectrometry) in the presence of symptoms or signs of TD.

The median baseline total testosterone in the TTh group was 327 ng/dL (IQR, 235-430). TTh modalities included transdermal formulations (gels, creams, patches), injectable agents (intramuscular testosterone cypionate or subcutaneous testosterone enanthate), and oral selective estrogen receptor modulators (clomiphene citrate and enclomiphene). AS monitoring followed an institutional protocol that included laboratory evaluations and digital rectal examination every 6 months, MRI every 18 months, and repeat biopsy every 36 months. The median follow-up for patients who did not progress was 6.7 years (IQR, 4.1-10.0).

The primary end point of the study was time to disease progression, defined as a histologic rise in grade group on biopsy (GG 1 to GG 2 or higher, or GG 2 to GG 3 or higher). The secondary end point was progression to definitive treatment, including surgery, RT, or focal therapy, for reasons other than biopsy-confirmed grade progression. An ascertainment bias analysis found no significant difference in biopsy frequency between patients receiving TTh and those who were not (Wilcoxon rank sum P = 0.7), supporting the validity of the progression comparison.

The investigators acknowledged several limitations. The TTh cohort was small (n = 79), yielding wide confidence intervals that cannot exclude a range from 33% lower to 50% higher hazard for grade progression compared with non-TTh patients. The observational design precluded adjustment for MRI findings, tumor volume, genomic risk, or the influence of clinician counseling on definitive treatment decisions: the latter limitation drove the choice of histologic progression as the primary, more objective end point.

The study adds to a growing body of evidence challenging the longstanding clinical assumption, rooted in Huggins and Hodges' 1941 observations, that exogenous testosterone activates or accelerates PCa. In a companion review published in the same journal issue and summarized in AUA News, Abraham Morgentaler, MD, associate clinical professor of urology at Harvard Medical School, and Abdulmaged Traish, PhD, of Boston University School of Medicine, examined 4 large randomized controlled trials of TTh and multiple meta-analyses.2 They reported finding no compelling evidence of increased PCa risk and concluded: "Contemporary evidence now overwhelmingly shows that this belief is false."2 Consistent with those findings, the phase 4 TRAVERSE trial (NCT03518034), a randomized, placebo-controlled study of testosterone-replacement therapy in more than 5000 hypogonadal men, recorded 12 PCa events in the testosterone arm vs 11 in the placebo arm over a mean follow-up of 33 months.

References

  1. Flores JM, Kim D, Yu R, et al. Testosterone therapy in men on active surveillance for prostate cancer is not associated with increased risk of disease progression. J Urol. 2026;216(6):805-813. doi:10.1097/JU.0000000000005276
  2. Morgentaler A, Traish A. Testosterone does not drive prostate cancer: a new era begins. AUA News. November/December 2026. Accessed November 20, 2026. https://tinyurl.com/mrt25yc5

Related to this article